Share on StockTwits
 

Avanir Pharmaceuticals (NASDAQ:AVNR) is set to post its quarterly earnings results on Wednesday, February 5th. Persons interested in listening to the company’s earnings conference call can do so using this link.

Avanir Pharmaceuticals (NASDAQ:AVNR) last announced its earnings results on Tuesday, December 10th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.02. The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $21.86 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 60.7% on a year-over-year basis. On average, analysts expect Avanir Pharmaceuticals to post $-0.25 EPS for the current fiscal year and $-0.11 EPS for the next fiscal year.

Shares of Avanir Pharmaceuticals (NASDAQ:AVNR) opened at 3.47 on Tuesday. Avanir Pharmaceuticals has a 52 week low of $2.60 and a 52 week high of $6.00. The stock has a 50-day moving average of $3.35 and a 200-day moving average of $4.30. The company’s market cap is $527.8 million.

AVNR has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Avanir Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, January 9th. They now have a $3.20 price target on the stock. Finally, analysts at Summer Street cut their price target on shares of Avanir Pharmaceuticals to $10.00 in a research note to investors on Wednesday, December 11th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Avanir Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $7.95.

AVANIR Pharmaceuticals, Inc (NASDAQ:AVNR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.